🔗 Share this article

An underground market for unapproved weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Experimental Treatment Gaining Traction Online

Retatrutide, which is still in clinical trials, is being promoted by online personalities for its alleged fat-burning properties. Viewers are urged to contact these profiles directly for source information, while also receiving discount codes.

Thriving Trade on Messaging Platforms

Additionally, a robust trade exists on messaging services, where communities with thousands of participants share comparison photos, injection guides and assertions of rapid British shipping. Vendors market the substance there before redirecting customers to other platforms for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injection created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Professionals Express Concerns

However, doctors and pharmacists have warned that the distribution of what is still an unapproved drug in the UK is a cause for concern and could lead to users administering products of unknown origin.

Some professionals said the demand for the experimental drug could be linked to the rising price of approved weight loss products such as Mounjaro.

Legal Status and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved drug that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several content creators try to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still violate pharmaceutical, advertising, and customer laws, potentially leading to fines, legal action or prison.

Platform Response and Material Elimination

Based on the social media company, the platform has taken down violative content and banned related hashtags and search suggestions. The company said it was dedicated to keeping the platform safe and investing in strengthening enforcement strategies.

Online Marketplace Activities

Research also found communities with up to 9,000 members selling the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, filled with images of slimming results, glowing reviews and detailed guides for mixing or administering at residence.

After moments of joining one group, a vendor posted contact information, where the majority of transactions occur. The vendor provided an guidebook and promised shipping within 48 hours. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. None inquired about weight, medical conditions or previous experience.

Item Information and Costs

Within these communities, messages show black plastic parcels with Royal Mail stickers, claiming to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with sterile water, or pre-filled injectors typically sold at £160 for 20 milligrams. When questioned how long a injector should be used, sellers give conflicting answers ranging from a several days to “depends on your body”.

Service Oversight and Safety Actions

A spokesperson for the messaging service stated it actively moderated dangerous material on its service including material that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are injecting materials they cannot confirm. Even if the science behind retatrutide is sound, these digital products may not include what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor linked the increase in demand to current cost increases for approved weight-loss medications such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But fake treatments are extremely risky. You cannot know what’s contained or whether the environment they were produced in was clean,” she said.

Her team has previously encountered individuals harmed by self-injection from unconfirmed sources. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your health,” stated the doctor. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet approved … may expose users to potentially serious medical dangers”.